Purpose

Dapagliflozin is a novel unique drug recently approved by the FDA for the treatment of type 2 diabetes. In previous studies, we found that in addition to lowering glucose sugar levels in the blood, dapagliflozin increases glucose sugar production by the liver and increases the rate of fat oxidationburning fat in the body. These actions of the drug decrease its effectivnessefficacy in lowering the blood sugar and increase the risk of complications. The aim of of the presentthis study is to understand the mechanism way by whichthat dapagliflozin causes the liver to increase sugar production and fat burning so that these actions, this allows us we can tothen develop methods to prevent them. You are being asked to be a participant in this study because you have type 2 diabetes and your blood sugar is not too high that requires treatment with medications. Or you do not have diabetes and the results of your tests will be used to compare to those with diabetes.

Category

IRB Number
20170214HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
Northwest Biotherapeutics -



Study Contact

Muhammad Abdul-Ghani
(210) 557-1157
abdulghani@uthscsa.edu

Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu

Principal Investigator
Muhammad Abdul-Ghani

Muhammad Abdul-Ghani
(210) 557-1157
abdulghani@uthscsa.edu

Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu

Michael Hewitt
+1 (210) 567-6691
hewittm@uthscsa.edu



Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Exclusion Criteria


      Study Design

      Arm Groups